지에프씨생명과학
Financials
Valuation Metrics
지에프씨생명과학's Market Cap is ₩314B. At end of 2025 it was ₩756B. Ranked #2035 of 2,436 in KR market (top 84%), #1291 of 1,649 on KOSDAQ (top 78%), #61 of 68 in Financial Services (top 90%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 31.42B KRW | KR#2,035/2,436 Sec#61/68 |
| Revenue | 17.71B KRW | KR#2,169/2,436 Sec#57/68 |
| Net Income | 555.4M KRW | KR#1,460/2,436 Sec#55/68 |
| Total Assets | 33.83B KRW | KR#2,304/2,436 Sec#60/68 |
| Net Assets | 23.80B KRW | KR#2,230/2,436 Sec#60/68 |
| Employees | 80 | KR#1,793/2,436 Sec#38/68 |
| Value | ||
| P/E | 56.57x | KR#1,372/2,436 Sec#54/68 |
| P/B | 1.32x | KR#1,709/2,436 Sec#47/68 |
| P/S | 1.77x | KR#1,762/2,436 Sec#40/68 |
| EV/EBITDA | 80.08x | KR#1,436/2,436 Sec#49/68 |
| FCF Yield | -20.19% | KR—/2,436 Sec—/68 |
| Profitability | ||
| ROE | 2.33% | KR#1,297/2,436 Sec#52/68 |
| ROA | 1.64% | KR#1,200/2,436 Sec#32/68 |
| Op. Margin | 2.18% | KR#1,339/2,436 Sec#53/68 |
| Revenue Growth | 5.42% | KR#1,144/2,436 Sec#43/68 |
| Financial Health | ||
| Debt Ratio | 42.16% | KR#154/2,436 Sec#1/68 |
| Total Debt | 6.98B KRW | KR#1,726/2,436 Sec#41/68 |
| FCF | -6.34B KRW | KR#1,570/2,436 Sec#31/68 |
| Cash | 7.47B KRW | KR#1,824/2,436 Sec#55/68 |
| Current Ratio | 5.60x | KR#248/2,436 Sec#4/68 |
| Net Debt/EBITDA | -1.26x | KR#411/2,436 Sec#19/68 |
| Performance | ||
| 1Y Return | -58.74% | KR#2,221/2,436 Sec#63/68 |
| 1M Return | 13.46% | KR#201/2,436 Sec#2/68 |
| From 52W High | -74.24% | KR#2,264/2,436 Sec#61/68 |
| 1Y MDD | -85.87% | KR#2,385/2,436 Sec#64/68 |
| Trading | ||
| Volume | 3,795 shares | KR#2,296/2,436 Sec#62/68 |
| Foreign Own. | 2.69% | KR—/2,436 Sec—/68 |
| Per Share | ||
| EPS | 145 KRW | KR#1,293/2,436 Sec#54/68 |
| BPS | 4,653 KRW | KR#1,498/2,436 Sec#45/68 |
Company Info
GFC Life Science, established in 2002, listed on KONEX in 2022 and transferred to KOSDAQ in 2025. The company specializes in developing and producing cosmetic biomaterials using skin microbiome and exosome technologies, alongside providing efficacy testing and advertising substantiation data for functional cosmetics. Leveraging a library of over 2,000 strains, more than 80 patented microorganisms, and patented exosome isolation and purification technology, it is actively developing skin booster products and pursuing global market expansion. GFC Life Science is headquartered in Hwaseong-si, Gyeonggi-do.